Stock KRON KRONOS BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Kronos Bio, Inc.

Equities

KRON

US50107A1043

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
0.98 USD +2.08% Intraday chart for Kronos Bio, Inc. -4.85% -21.60%
Mar. 21 Earnings Flash (KRON) KRONOS BIO Reports Q4 Revenue $2.3M MT
Mar. 21 Kronos Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Evolution of the average Target Price on Kronos Bio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

c77975fe85980518fb55ef.laABpA1-QK-Xx7BVlfNcgb5Br_d-x9GFvvBy_556Ws0.1sJx6TkOKeWunfk9250kyNkywcYpi5jz9Zwdp645K4LUlFn8OkkG6tm2iA~82b30f3d1c92d2dbdd0b52e76e8270a2

Analyst Recommendations on Kronos Bio, Inc.

Investors got more clues that rate cuts are imminent Our Logo
Piper Sandler Trims Price Target on Kronos Bio to $6 From $7, Keeps Overweight Rating MT
HC Wainwright Adjusts Price Target on Kronos Bio to $2.50 From $9, Keeps Buy Rating MT
HC Wainwright Adjusts Price Target on Kronos Bio to $9 From $10, Maintains Buy Rating MT
Goldman Sachs Cuts Price Target on Kronos Bio to $14 From $25, Maintains Buy Rating MT
Piper Sandler Lowers Price Target on Kronos Bio to $7 From $13, Maintains Overweight Rating MT
Berenberg Bank Adjusts Kronos Bio Price Target to $11 From $12, Maintains Buy Rating MT
Berenberg Bank Initiates Coverage on Kronos Bio With Buy Rating, $12 Price Target MT
Goldman Sachs Adjusts Price Target for Kronos Bio to $25 From $23, Maintains Buy Rating MT
Goldman Sachs Adjusts Price Target for Kronos Bio to $23 From $35, Reiterates Buy Rating MT
Piper Sanler Lowers Kronos Bio's Price Target to $13 From $30, Maintains Overweight Rating MT
Piper Sandler Adjusts Kronos Bio's Price Target to $30 From $50, Reiterates Overweight Rating MT
KRONOS BIO : HC Wainwright Starts Kronos Bio at Buy With $35 Price Target MT
Kronos Bio : Posts Wider Q3 Net Loss Than Analysts' Expectations MT
KRONOS BIO : Jefferies Starts Kronos Bio at Buy With $36 Price Target MT
KRONOS BIO : Piper Sandler Starts Kronos Bio at Overweight With $50 Price Target MT
KRONOS BIO : Goldman Sachs Starts Kronos Bio at Buy With $45 Price Target MT
KRONOS BIO : Cowen Initiates Coverage on Kronos Bio With Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.98 USD
Average target price
4.25 USD
Spread / Average Target
+333.67%
High Price Target
6 USD
Spread / Highest target
+512.24%
Low Price Target
2.5 USD
Spread / Lowest Target
+155.10%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Kronos Bio, Inc.

Piper Sandler
HC Wainwright
Goldman Sachs
Berenberg Bank

Ratings for Kronos Bio, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. KRON Stock
  4. Consensus Kronos Bio, Inc.